STOCK TITAN

[Form 4] ZIMMER BIOMET HOLDINGS, INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Devdatt Kurdikar, a Director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 140.163 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The derivative units convert on a 1-for-1 basis into common stock and are scheduled to be settled in shares within sixty days after the director’s service ends. The report shows 1,613.887 shares of common stock beneficially owned following the reported transaction, and it notes 3.428 phantom units were added on 07/31/2025 via the plan’s dividend reinvestment provision.

Devdatt Kurdikar, un Direttore di Zimmer Biomet Holdings, Inc. (ZBH), ha riportato su Form 4 che 140.163 unità di azioni fantasma sono state acquisite il 09/30/2025 ai sensi del piano di compensazione differita per i direttori non dipendenti della società. Le unità derivate si trasformano in azioni ordinarie su base 1-for-1 e sono previste per essere liquidate in azioni entro sessanta giorni dopo la cessazione della carica del direttore. Il rapporto mostra 1.613.887 azioni ordinarie possedute beneficiariamente a seguito della transazione riportata, e segnala che 3.428 unità fantasma sono state aggiunte il 31/07/2025 tramite la disposizione di reinvestimento dei dividendi del piano.

Devdatt Kurdikar, un Director de Zimmer Biomet Holdings, Inc. (ZBH), informó en Form 4 que se adquirieron 140.163 unidades fantasma el 30/09/2025 bajo el Plan de Compensación Diferida para Directores No Empleados de la empresa. Las unidades derivadas se convierten a acciones ordinarias en una base 1-para-1 y se espera que se liquiden en acciones dentro de sesenta días después de que termine el servicio del director. El informe muestra 1.613.887 acciones ordinarias beneficiosamente poseídas tras la transacción reportada, y señala que 3.428 unidades fantasma se añadieron el 31/07/2025 mediante la disposición de reinversión de dividendos del plan.

Devdatt Kurdikar, 한 이사 Zimmer Biomet Holdings, Inc. (ZBH)의 폼 4에 보고된 바에 따르면 회사의 비피고용 이사를 위한 이연보상 계획에 따라 2025-09-30140.163개의 팬텀 주식 단위가 취득되었습니다. 파생 단위는 1대 1의 비율로 보통주로 전환되며 이사는 재임 종료 후 60일 이내에 주식으로 정산될 예정입니다. 보고서는 보고된 거래 후 이익 소유의 일반주 1,613.887주를 보여주고, 계획의 배당 재투자 조항을 통해 2025-07-313.428개의 팬텀 단위가 추가되었다고 명시합니다.

Devdatt Kurdikar, un Directeur de Zimmer Biomet Holdings, Inc. (ZBH), a déclaré dans le Form 4 que 140.163 unités d’actions fantômes ont été acquises le 30/09/2025 dans le cadre du Plan de rémunération différée pour les administrateurs non salariés de l’entreprise. Les unités dérivées se convertissent sur une base 1 pour 1 en actions ordinaires et devraient être réglées en actions dans les soixante jours suivant la fin du mandat du directeur. Le rapport indique 1.613.887 actions ordinaires détenues bénéficiaires après la transaction rapportée, et note que 3.428 unités fantômes ont été ajoutées le 31/07/2025 via la disposition de réinvestissement des dividendes du plan.

Devdatt Kurdikar, ein Direktor von Zimmer Biomet Holdings, Inc. (ZBH), meldete im Formular 4, dass am 30.09.2025 140.163 Phantomaktien-Einheiten im Rahmen des Deferred Compensation Plans für Nicht-Mitarbeiter-Direktoren des Unternehmens erworben wurden. Die Derivateinheiten wandeln sich 1:1 in Stammaktien um und sollen innerhalb von sechzig Tagen nach Beendigung der Dienstzeit des Direktors in Aktien abgewickelt werden. Der Bericht weist nach der gemeldeten Transaktion 1.613.887 Stammaktien aus, die vorteilhaft gehalten werden, und vermerkt, dass am 31.07.2025 über die Dividenden-Reinvestitionsbestimmung des Plans 3.428 Phantom-Einheiten hinzugefügt wurden.

Devdatt Kurdikar, مدير في Zimmer Biomet Holdings, Inc. (ZBH)، أبلغ في النموذج 4 أن 140.163 وحدة أسهم فانتوم اكتُسبت في 30/09/2025 بموجب خطة التعويض المؤجل للمديرين غير الموظفين بالشركة. الوحدات المشتقة تتحول إلى أسهم عادية بنسبة 1-إلى-1 ومن المقرر تسويتها بالأسهم خلال ستين يوماً بعد انتهاء خدمة المدير. يظهر التقرير 1.613.887 سهماً عاقد الملكية التالية للصفقة المبلغ عنها، ويشير إلى أن 3.428 وحدة فانتوم أُضيفت في 31/07/2025 بموجب بند إعادة استثمار الأرباح في الخطة.

Devdatt Kurdikar, Zimmer Biomet Holdings, Inc.(ZBH)的董事,在公司为非员工董事设立的延期补偿计划下,通过 Form 42025-09-30 收购了 140.163 份幻影股票单位。该衍生单位按 1-对-1 的比例转换为普通股,计划在董事任期结束后的 六十天 内以股票结算。报告显示交易后实际持有的普通股为 1.613.887 股,并指出在 2025-07-31 通过计划的股息再投资条款新增了 3.428 份幻影单位。

Positive
  • None.
Negative
  • None.

Insights

Form 4 records director compensation in deferred phantom stock units and current beneficial ownership.

What it means: The filing documents non-employee director compensation that vests as phantom stock units (140.163 units on 09/30/2025) which convert 1-for-1 into common shares. These units are part of the company’s deferred compensation plan and are payable in shares within sixty days after the director stops serving.

Why it matters: Director-held deferred equity aligns a director’s economic interest with shareholders without immediate stock issuance. The filing also discloses total reported beneficial ownership of 1,613.887 shares, a fact investors can use to track insider alignment and potential future share issuance upon settlement.

Devdatt Kurdikar, un Direttore di Zimmer Biomet Holdings, Inc. (ZBH), ha riportato su Form 4 che 140.163 unità di azioni fantasma sono state acquisite il 09/30/2025 ai sensi del piano di compensazione differita per i direttori non dipendenti della società. Le unità derivate si trasformano in azioni ordinarie su base 1-for-1 e sono previste per essere liquidate in azioni entro sessanta giorni dopo la cessazione della carica del direttore. Il rapporto mostra 1.613.887 azioni ordinarie possedute beneficiariamente a seguito della transazione riportata, e segnala che 3.428 unità fantasma sono state aggiunte il 31/07/2025 tramite la disposizione di reinvestimento dei dividendi del piano.

Devdatt Kurdikar, un Director de Zimmer Biomet Holdings, Inc. (ZBH), informó en Form 4 que se adquirieron 140.163 unidades fantasma el 30/09/2025 bajo el Plan de Compensación Diferida para Directores No Empleados de la empresa. Las unidades derivadas se convierten a acciones ordinarias en una base 1-para-1 y se espera que se liquiden en acciones dentro de sesenta días después de que termine el servicio del director. El informe muestra 1.613.887 acciones ordinarias beneficiosamente poseídas tras la transacción reportada, y señala que 3.428 unidades fantasma se añadieron el 31/07/2025 mediante la disposición de reinversión de dividendos del plan.

Devdatt Kurdikar, 한 이사 Zimmer Biomet Holdings, Inc. (ZBH)의 폼 4에 보고된 바에 따르면 회사의 비피고용 이사를 위한 이연보상 계획에 따라 2025-09-30140.163개의 팬텀 주식 단위가 취득되었습니다. 파생 단위는 1대 1의 비율로 보통주로 전환되며 이사는 재임 종료 후 60일 이내에 주식으로 정산될 예정입니다. 보고서는 보고된 거래 후 이익 소유의 일반주 1,613.887주를 보여주고, 계획의 배당 재투자 조항을 통해 2025-07-313.428개의 팬텀 단위가 추가되었다고 명시합니다.

Devdatt Kurdikar, un Directeur de Zimmer Biomet Holdings, Inc. (ZBH), a déclaré dans le Form 4 que 140.163 unités d’actions fantômes ont été acquises le 30/09/2025 dans le cadre du Plan de rémunération différée pour les administrateurs non salariés de l’entreprise. Les unités dérivées se convertissent sur une base 1 pour 1 en actions ordinaires et devraient être réglées en actions dans les soixante jours suivant la fin du mandat du directeur. Le rapport indique 1.613.887 actions ordinaires détenues bénéficiaires après la transaction rapportée, et note que 3.428 unités fantômes ont été ajoutées le 31/07/2025 via la disposition de réinvestissement des dividendes du plan.

Devdatt Kurdikar, ein Direktor von Zimmer Biomet Holdings, Inc. (ZBH), meldete im Formular 4, dass am 30.09.2025 140.163 Phantomaktien-Einheiten im Rahmen des Deferred Compensation Plans für Nicht-Mitarbeiter-Direktoren des Unternehmens erworben wurden. Die Derivateinheiten wandeln sich 1:1 in Stammaktien um und sollen innerhalb von sechzig Tagen nach Beendigung der Dienstzeit des Direktors in Aktien abgewickelt werden. Der Bericht weist nach der gemeldeten Transaktion 1.613.887 Stammaktien aus, die vorteilhaft gehalten werden, und vermerkt, dass am 31.07.2025 über die Dividenden-Reinvestitionsbestimmung des Plans 3.428 Phantom-Einheiten hinzugefügt wurden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Kurdikar Devdatt

(Last) (First) (Middle)
345 E. MAIN STREET

(Street)
WARSAW IN 45680

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units(1) $98.1(2) 09/30/2025 A 140.163 (3) (3) Common Stock 140.163 $0 1,613.887(4) D
Explanation of Responses:
1. The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
2. The Conversion or Exercise Price of Derivative Security is 1-for-1.
3. The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
4. Includes 3.428 phantom stock units accrued on July 31, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
/s/ Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kuridkar (power of attorney previously filed) 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Devdatt Kurdikar report on the Form 4 for ZBH?

He reported acquisition of 140.163 phantom stock units on 09/30/2025 under the Deferred Compensation Plan for Non-Employee Directors.

How do the phantom stock units convert for ZBH director compensation?

The units convert on a 1-for-1 basis into common stock and are to be settled in shares within sixty days after cessation of the director's service.

How many shares does the Form 4 show as beneficially owned after the transaction?

The filing shows 1,613.887 shares of common stock beneficially owned following the reported transaction.

Did dividend reinvestment affect the phantom units?

Yes. The filing states 3.428 phantom stock units were accrued on 07/31/2025 under the plan's dividend reinvestment provision.

When was the Form 4 signed and filed?

The Form 4 is signed by Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kurdikar and dated 10/02/2025.
Zimmer Biomet

NYSE:ZBH

ZBH Rankings

ZBH Latest News

ZBH Latest SEC Filings

ZBH Stock Data

19.65B
197.78M
0.15%
98.95%
2.93%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WARSAW